Hoth Therapeutics (HOTH) Unveils New Strategic Investor Presentation Materials

Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025.

Rhea-AI Filing Summary

Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.

Key points from the filing:

• The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
• The company maintains discretion to update the materials but has no obligation to do so
• Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
• The information will not be incorporated by reference into any Securities Act or Exchange Act filings

The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HOTH announce in their 8-K filing on June 24, 2025?

HOTH announced the preparation of new presentation materials that management plans to use from time to time starting June 24, 2025, to present information about the company's business. These presentation materials were furnished as Exhibit 99.1 to the Current Report.

Who signed HOTH's June 24, 2025 8-K filing?

The 8-K was signed by Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc.

What exhibits were included in HOTH's June 2025 8-K filing?

The filing included two exhibits: Exhibit 99.1 (Presentation Materials dated June 2025) and Exhibit 104 (Cover Page Interactive Data File formatted as Inline XBRL).

Is HOTH required to update the presentation materials disclosed in the June 2025 8-K?

No, while HOTH may elect to update the presentation materials in the future, the company specifically disclaims any obligation to do so. The materials speak as of the date of the Current Report.

Will HOTH's presentation materials be considered 'filed' under SEC regulations?

No, the information in Item 7.01 and Exhibit 99.1 is explicitly stated to be 'furnished' and not 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, and will not be incorporated by reference into any future SEC filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:05 PM EDT Learn about SEC filing dates

false 0001711786 0001711786 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 24, 2025

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-38803		82-1553794
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

1177 Avenue of the Americas, 5th Floor, Suite 066

New York, NY 10036

(Address of principal executive offices, including ZIP code)

(646) 756-2997

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		HOTH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01. Regulation FD Disclosure.

Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after June 24, 2025 in presentations about the Company’s business. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in the Presentation Materials is summary information that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

Item 9.01. Financial Statements and Exhibits.

d) Exhibits

Exhibit No.		Description
99.1		Presentation Materials dated June 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL)

-1-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 24, 2025	Hoth Therapeutics, Inc.
	/s/ Robb Knie
	Robb Knie
	Chief Executive Officer

-2-